RELMADA THERAPEUTICS, INC. Diluted Shares Outstanding (Weighted Average)
RELMADA THERAPEUTICS, INC. (RLMD) reported Diluted Shares Outstanding (Weighted Average) of 112.38 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 112.38M shares, a 238.57% increase year-over-year.
- RELMADA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 86.60M shares, a 184.77% increase year-over-year.
- RELMADA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 61.10M shares, a 102.48% increase year-over-year.
- RELMADA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 33.19M shares, a 10.00% increase year-over-year.
- RELMADA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2025 was 39.48M shares, a 30.88% increase from fiscal 2024.
- RELMADA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2024 was 30.16M shares, a 0.21% increase from fiscal 2023.
- RELMADA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2023 was 30.10M shares, a 1.59% increase from fiscal 2022.
- RELMADA THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2022 was 29.63M shares, a 68.80% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 112.38M shares 10-Q · filed 2026-08-06 | 99.33M shares 10-Q · filed 2026-08-06 | 86.69M shares derived: average of 3 quarters · filed 2026-08-06 | 73.32M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 86.60M shares 10-Q · filed 2026-05-12 | 73.85M shares derived: average of 2 quarters · filed 2026-05-12 | 60.29M shares derived: average of 3 quarters · filed 2026-05-12 | 53.52M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 61.10M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 47.14M shares derived: average of 2 quarters · filed 2026-03-19 | 42.49M shares derived: average of 3 quarters · filed 2026-08-06 | 39.48M shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 33.19M shares 10-Q · filed 2025-11-13 | 33.19M shares derived: average of 2 quarters · filed 2026-08-06 | 32.27M shares 10-Q · filed 2025-11-13 | 31.74M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 33.19M shares 10-Q · filed 2026-08-06 | 31.81M shares 10-Q · filed 2026-08-06 | 31.26M shares derived: average of 3 quarters · filed 2026-08-06 | 30.99M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 30.41M shares 10-Q · filed 2026-05-12 | 30.29M shares derived: average of 2 quarters · filed 2026-05-12 | 30.25M shares derived: average of 3 quarters · filed 2026-05-12 | 30.23M shares derived: average of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | 30.17M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 30.17M shares derived: average of 2 quarters · filed 2026-03-19 | 30.17M shares derived: average of 3 quarters · filed 2026-03-19 | 30.16M shares 10-K · filed 2026-03-19 |
| 2024-09-30 | 30.17M shares 10-Q · filed 2025-11-13 | 30.17M shares derived: average of 2 quarters · filed 2025-11-13 | 30.16M shares 10-Q · filed 2025-11-13 | 30.14M shares derived: average of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | 30.17M shares 10-Q · filed 2025-08-07 | 30.15M shares 10-Q · filed 2025-08-07 | 30.14M shares derived: average of 3 quarters · filed 2025-08-07 | 30.13M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 30.13M shares 10-Q · filed 2025-05-12 | 30.12M shares derived: average of 2 quarters · filed 2025-05-12 | 30.11M shares derived: average of 3 quarters · filed 2025-05-12 | 30.11M shares derived: average of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | 30.10M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 30.10M shares derived: average of 2 quarters · filed 2025-03-27 | 30.10M shares derived: average of 3 quarters · filed 2025-03-27 | 30.10M shares 10-K · filed 2025-03-27 |
| 2023-09-30 | 30.10M shares 10-Q · filed 2024-11-07 | 30.10M shares derived: average of 2 quarters · filed 2024-11-07 | 30.10M shares 10-Q · filed 2024-11-07 | 30.10M shares derived: average of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | 30.10M shares 10-Q · filed 2024-08-07 | 30.10M shares 10-Q · filed 2024-08-07 | 30.10M shares derived: average of 3 quarters · filed 2024-08-07 | 30.09M shares derived: average of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | 30.10M shares 10-Q · filed 2024-05-08 | 30.10M shares derived: average of 2 quarters · filed 2024-05-08 | 30.09M shares derived: average of 3 quarters · filed 2024-05-08 | 30.05M shares derived: average of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | 30.10M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 30.08M shares derived: average of 2 quarters · filed 2024-03-19 | 30.03M shares derived: average of 3 quarters · filed 2024-03-19 | 29.63M shares 10-K · filed 2024-03-19 |
| 2022-09-30 | 30.06M shares 10-Q · filed 2023-11-08 | 30.00M shares derived: average of 2 quarters · filed 2023-11-08 | 29.47M shares 10-Q · filed 2023-11-08 | 26.87M shares derived: average of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | 29.94M shares 10-Q · filed 2023-08-08 | 29.17M shares 10-Q · filed 2023-08-08 | 25.81M shares derived: average of 3 quarters · filed 2023-08-08 | 23.73M shares derived: average of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 28.39M shares 10-Q · filed 2022-05-05 | 23.74M shares derived: average of 2 quarters · filed 2023-03-23 | 21.66M shares derived: average of 3 quarters · filed 2023-03-23 | 20.51M shares derived: average of 4 quarters · filed 2023-03-23 |
| 2021-12-31 | 19.10M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | 18.29M shares derived: average of 2 quarters · filed 2023-03-23 | 17.88M shares derived: average of 3 quarters · filed 2023-03-23 | 17.55M shares 10-K · filed 2023-03-23 |
| 2021-09-30 | 17.48M shares 10-Q · filed 2022-11-10 | 17.27M shares derived: average of 2 quarters · filed 2022-11-10 | 17.04M shares 10-Q · filed 2022-11-10 | |
| 2021-06-30 | 17.05M shares 10-Q · filed 2022-08-11 | 16.81M shares 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | 16.57M shares 10-Q · filed 2022-05-05 | |||
| 2017-03-31 | 12.04M shares 10-Q · filed 2017-05-15 | 12.04M shares derived: average of 2 quarters · filed 2017-05-15 | 12.04M shares 10-Q · filed 2017-05-15 | |
| 2016-12-31 | 12.04M shares 10-Q · filed 2017-02-10 | 12.04M shares 10-Q · filed 2017-02-10 | ||
| 2016-09-30 | 12.04M shares 10-Q · filed 2016-11-10 | |||
| 2016-03-31 | 12.00M shares 10-Q · filed 2017-05-15 | 11.71M shares derived: average of 2 quarters · filed 2017-05-15 | 12.14M shares 10-Q · filed 2017-05-15 | |
| 2015-12-31 | 11.42M shares 10-Q · filed 2017-02-10 | 11.86M shares 10-Q · filed 2017-02-10 | ||
| 2015-09-30 | 12.94M shares 10-Q · filed 2016-11-10 | |||
| 2015-03-31 | 10.74M shares 10-Q · filed 2016-05-09 | 12.41M shares derived: average of 2 quarters · filed 2016-05-09 | 9.67M shares 10-Q · filed 2016-05-09 | |
| 2014-12-31 | 14.09M shares 10-Q · filed 2016-02-05 | 9.15M shares 10-Q · filed 2016-02-05 | ||
| 2014-09-30 | 8.15M shares 10-Q · filed 2015-11-06 | |||
| 2014-03-31 | 209.61M shares 8-K · filed 2014-05-27 | |||
| 2013-12-31 | 24.29M shares 8-K · filed 2014-05-27 | |||
| 2013-03-31 | 24.02M shares 8-K · filed 2014-05-27 | |||
| 2012-12-31 | 21.66M shares 8-K · filed 2014-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |